Epitopea's Growing Clinical and Research Division
Epitopea, a transatlantic cancer immunotherapeutics company, is at the forefront of developing innovative RNA-based immunotherapies. The company recently announced the formation of a dedicated clinical team and the expansion of its research division, marking a significant milestone as it accelerates its immunotherapies, known as CryptiVax™, into clinical trials.
New Additions to Executive Leadership
With the recent appointments of Siri Brinchmann-Hansen Torhaug as Head of Oncology Development and Gertrud Koefoed Rasmussen as Head of Development Operations, Epitopea is enhancing its executive leadership team. Both leaders will report to Dr. Klaus Edvardsen, the Chief Medical Officer, who is guiding the company's strategic direction in clinical trials and regulatory affairs.
Experience in the Field
Siri Brinchmann-Hansen Torhaug arrives with a wealth of experience as an oncology specialist, having held senior positions, including Chief Medical Officer at Nykode Therapeutics. Her role will be critical in shaping clinical strategies to propel Epitopea’s innovative pipeline forward, all with the goal of improving patients' outcomes.
Focus on Strategic Development
In her new role, Torhaug expressed enthusiasm about joining Epitopea, stating, "This is an exciting opportunity to contribute to the company's groundbreaking work in cancer immunotherapy alongside Klaus and Gertrud." Her focus will be on ensuring that the company’s therapeutic pipeline is executed with precision.
Expanding Research Capabilities
As the clinical team takes shape, the research department has also been strengthened with the addition of Dr. Theres Oakes as Director of Translational Sciences and Dr. Lisa Smith as Director of Research (UK). This expansion will enhance translational immunology capabilities, allowing for a seamless integration of research and clinical strategies.
Innovations in Immuno-Oncology
Dr. Theres Oakes brings a robust background in antigen-directed immuno-oncology, which she honed in previous roles and academic pursuits. Together with Dr. Lisa Smith, who boasts significant expertise in drug discovery from her time at various therapeutic firms, these appointments are designed to elevate Epitopea’s research output and its ability to innovate within the field.
The Vision for Future Therapies
Dr. Klaus Edvardsen emphasizes the importance of forming a strong clinical team, accentuating the invaluable skills and insights that Gertrud and Siri bring to Epitopea. Their leadership is pivotal as the company navigates clinical trials, aspiring to deliver its innovative cancer therapies to those in need.
Commitment to Patients
Gertrud Koefoed Rasmussen elucidated her excitement in joining the team, saying, "I am eager to leverage my expertise in clinical operations to bring forth innovative therapies that address significant unmet medical needs in oncology." This reflects Epitopea's commitment to improving patient outcomes by managing trials efficiently and adhering closely to regulatory standards.
About Epitopea
Founded in 2021, Epitopea is dedicated to producing accessible, off-the-shelf RNA-based immunotherapies targeting difficult cancers by focusing on a new category of tumor-specific antigens known as Cryptigen™ TSAs. These antigens are broadly shared among patients suffering from the same type of tumor, which highlights Epitopea's unique approach to cancer treatment.
Utilizing Advanced Technology
Epitopea has developed a significant library of novel Cryptigen™ TSAs through its proprietary CryptoMap™ platform. This platform integrates immunopeptidomics, genomics, and a bioinformatics pipeline to identify aberrantly-expressed tumor-specific antigens hidden in cancer's 'junk' DNA. This innovative methodology underpins the company's research and development strategy.
Investments and Collaborations
Epitopea is supported by top-tier life science investors and has established a license and research collaboration with MSD (the tradename of Merck & Co., Inc.). Such relationships are fostering the advancements of their groundbreaking therapies, ensuring the company remains at the cutting edge of cancer treatment.
A Goal to Impact Treatment
Dr. Jon Moore, Co-founder and Chief Scientific Officer, highlighted the aim of building a world-class team dedicated to developing cancer immunotherapeutics. He is optimistic about the impact these innovations will have on treating diseases that affect countless patients worldwide.
Frequently Asked Questions
What recent changes have been made to the Epitopea team?
Epitopea has expanded its executive leadership by appointing Siri Brinchmann-Hansen Torhaug and Gertrud Koefoed Rasmussen to crucial roles in oncology and development operations.
How does Epitopea’s research focus differ from others?
The company's research focuses on developing RNA-based immunotherapies that target unique tumor-specific antigens found in difficult-to-treat cancers.
What is the significance of the new appointments?
The new appointments enhance Epitopea's clinical strategies and operational efficiencies, thereby accelerating the company's development of innovative therapies.
What is the CryptoMap™ platform?
CryptoMap™ is Epitopea's proprietary platform designed to discover novel tumor-specific antigens by leveraging technology in immunopeptidomics and genomics.
How is patient outcome a priority for Epitopea?
Epitopea is committed to advancing its therapies in a manner that aims to significantly improve patient outcomes in cancer treatment.
